Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. 1997

R J Gilson, and A E Hawkins, and M R Beecham, and E Ross, and J Waite, and M Briggs, and T McNally, and G E Kelly, and R S Tedder, and I V Weller
Department of Sexually transmitted Diseases, University College London Medical School, UK.

OBJECTIVE Hepatitis B virus (HBV) and HIV infections share risk-factors; therefore coinfection is common. Interactions have been reported but controlled studies have been limited. Our objective was to study the effect of HIV infection on the natural history of chronic HBV infection and the reverse effect of the HBV carrier state on HIV infection. METHODS Prospective observational cohort study. METHODS Open-access outpatient HIV/genitourinary medicine clinic at a Central London hospital. METHODS Total of 152 untreated homosexual male HBV carriers and 212 HBV surface antigen-negative controls (41.4 and 70.3% HIV-seropositive, respectively). METHODS The rate of loss of serum HBV e antigen (HBeAg) and its reappearance in HIV-infected and HIV-uninfected HBV carriers; serum HBV DNA levels measured by dot-blot hybridization assay), HBV DNA polymerase activity and liver transaminase activities, the progression of HIV infection to symptomatic disease or AIDS in HIV-infected compared with HBV-HIV coinfected patients. RESULTS In HIV-infected HBV carriers, serum HBV DNA polymerase activity was higher, alanine aminotransferase was lower and loss of serum HBeAg (mean follow-up, 2.8 years) occurred at a lower rate when compared with HIV-uninfected HBV carriers (estimated relative hazard, 0.39; 95% confidence interval, 0.161-0.942) Concomitant chronic HBV infection had no detectable effect on the rate of progression of HIV disease after correction for lead-time bias. CONCLUSIONS This study strengthens the evidence for a significant effect of HIV infection on the natural history of chronic HBV infection, which by prolonging the period of infectivity could have an important impact on the epidemiology of HBV infection in regions, or patient groups, with high HIV seroprevalence. There was no evidence of an important effect of HBV carriage on HIV disease progression.

UI MeSH Term Description Entries
D008297 Male Males
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D006509 Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Hepatitis B Virus Infection
D006515 Hepatitis B virus The type species of the genus ORTHOHEPADNAVIRUS which causes human HEPATITIS B and is also apparently a causal agent in human HEPATOCELLULAR CARCINOMA. The Dane particle is an intact hepatitis virion, named after its discoverer. Non-infectious spherical and tubular particles are also seen in the serum. Dane Particle,Hepatitis Virus, Homologous Serum,B virus, Hepatitis,Hepatitis B viruses,Particle, Dane,viruses, Hepatitis B
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D015331 Cohort Studies Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics. Birth Cohort Studies,Birth Cohort Study,Closed Cohort Studies,Cohort Analysis,Concurrent Studies,Historical Cohort Studies,Incidence Studies,Analysis, Cohort,Cohort Studies, Closed,Cohort Studies, Historical,Studies, Closed Cohort,Studies, Concurrent,Studies, Historical Cohort,Analyses, Cohort,Closed Cohort Study,Cohort Analyses,Cohort Studies, Birth,Cohort Study,Cohort Study, Birth,Cohort Study, Closed,Cohort Study, Historical,Concurrent Study,Historical Cohort Study,Incidence Study,Studies, Birth Cohort,Studies, Cohort,Studies, Incidence,Study, Birth Cohort,Study, Closed Cohort,Study, Cohort,Study, Concurrent,Study, Historical Cohort,Study, Incidence
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human

Related Publications

R J Gilson, and A E Hawkins, and M R Beecham, and E Ross, and J Waite, and M Briggs, and T McNally, and G E Kelly, and R S Tedder, and I V Weller
November 1994, Lancet (London, England),
R J Gilson, and A E Hawkins, and M R Beecham, and E Ross, and J Waite, and M Briggs, and T McNally, and G E Kelly, and R S Tedder, and I V Weller
January 1995, Lancet (London, England),
R J Gilson, and A E Hawkins, and M R Beecham, and E Ross, and J Waite, and M Briggs, and T McNally, and G E Kelly, and R S Tedder, and I V Weller
January 1995, Lancet (London, England),
R J Gilson, and A E Hawkins, and M R Beecham, and E Ross, and J Waite, and M Briggs, and T McNally, and G E Kelly, and R S Tedder, and I V Weller
January 1989, Gastroenterologie clinique et biologique,
R J Gilson, and A E Hawkins, and M R Beecham, and E Ross, and J Waite, and M Briggs, and T McNally, and G E Kelly, and R S Tedder, and I V Weller
January 1987, Hepatology (Baltimore, Md.),
R J Gilson, and A E Hawkins, and M R Beecham, and E Ross, and J Waite, and M Briggs, and T McNally, and G E Kelly, and R S Tedder, and I V Weller
May 2011, Nihon rinsho. Japanese journal of clinical medicine,
R J Gilson, and A E Hawkins, and M R Beecham, and E Ross, and J Waite, and M Briggs, and T McNally, and G E Kelly, and R S Tedder, and I V Weller
August 2020, Current HIV/AIDS reports,
R J Gilson, and A E Hawkins, and M R Beecham, and E Ross, and J Waite, and M Briggs, and T McNally, and G E Kelly, and R S Tedder, and I V Weller
December 1988, Chemioterapia : international journal of the Mediterranean Society of Chemotherapy,
R J Gilson, and A E Hawkins, and M R Beecham, and E Ross, and J Waite, and M Briggs, and T McNally, and G E Kelly, and R S Tedder, and I V Weller
July 1983, Annals of internal medicine,
R J Gilson, and A E Hawkins, and M R Beecham, and E Ross, and J Waite, and M Briggs, and T McNally, and G E Kelly, and R S Tedder, and I V Weller
August 1983, The British journal of venereal diseases,
Copied contents to your clipboard!